Use of Gastric Bypass Surgery for the Treatment of Type 2 Diabetes Mellitus by Sanders, Kaitlin A. et al.
Pharmacy and Wellness Review 
Volume 1 Issue 2 Article 4 
November 2010 
Use of Gastric Bypass Surgery for the Treatment of Type 2 
Diabetes Mellitus 
Kaitlin A. Sanders 
Ohio Northern University 
Jenna L. Schaffner 
Ohio Northern University 
Leslie M. Hart 
Ohio Northern University 
Whitney N. Detillion 
Ohio Northern University 
Anne Gentry 
Ohio Northern University 
Follow this and additional works at: https://digitalcommons.onu.edu/paw_review 
 Part of the Endocrinology, Diabetes, and Metabolism Commons, Other Pharmacy and Pharmaceutical 
Sciences Commons, and the Surgery Commons 
This Article is brought to you for free and open access by 
the ONU Journals and Publications at 
DigitalCommons@ONU. It has been accepted for 
inclusion in Pharmacy and Wellness Review by an 
authorized editor of DigitalCommons@ONU. For more 
information, please contact digitalcommons@onu.edu. 
Use of Gastric Bypass Surgery for the Treatment of Type 2 Diabetes Mellitus 
Kaitlin A. Sanders, fifth-year pharmacy student from Kendallville, Ind.; Jenna L. Schaffner, fifth-year pharmacy student from North Canton, Ohio; 
Leslie M. Hart, sixth-year pharmacy student from Cooperstown, Pa.; Whitney N. Detillion, sixth-year pharmacy student from Portsmouth, Ohio; Anne Gentry, PharmD 
Abstract: 
Over the past decade, the incidence of type 2 diabetes mellitus 
(T20M) has increasecl significantly. Evidence has shown tflat a clear 
association exists between obesity and diabetes development. This 
association has inspired researchers lo explore bariatric surgery as 
an option tor diabetes management and possible disease reversal. 
Improvement of T20M using Roux-En-Y gastric bypaas (RYGB) 
is l1'lought to resuh from a combination of weight loss, decreased 
caloric intake, hormonal changes and rearrangement of the gastro-
intestinal anatomy. Positive outcomes resulting from the procedure 
include decreased mortality rates, normalization of HbA1c levels, 
decreased dependence on cfiabetic medical.ions, and increased 
insulin sensitivity. Gastric bypass, specifically RYGB. appears to be 
a promising treatment for T2DM. Due to possible complications and 
llmlted research in some populations, treatment should be restricted 
to patients with a BMI > 35 with concurrent diabetes. Patients with 
dltbetes who qualify shoufd be counseled on the potential benefits 
of gastric bypass as a Viable op1ion for diabetes management. 
Introduction: 
The incidence of type 2 diabetes mellitus (T2DM) is rapidly increasing 
worldwide and is stated to be the sixth leading cause of death in the U.S.1 
More than 24 million Americans have been diagnosed with diabetes, and 
approximately 800,000 new cases arise each year.2Between 1995 and 
2025, prevalence is expected to increase from 130 million to roughly 300 
million.3 Although causation cannot be linked to one specific source, rising 
diabetes rates are undeniably associated with the obesity epidemic. In 
Western countries, 15-30 percent of the adult population is obese (BMI 
> 30). Studies have observed that insulin resistance and diabetes often 
follow a large increase in body weight. One such study, the Nurses' Health 
Study, found that both men and women who gain 11-19.9 kg after the age 
of 18 have 5.5 times the risk of developing T2DM.3 Furthermore, other 
analyses have linked centrally patterned fat distribution with an increased 
diabetic risk. Therefore, the development of diabetes depends not only on 
ilfestyle choices, but also on genetic components. 
Patients with T2DM account for approximately 90 percent of all diabet-
ics. 4 One characteristic commonly seen in T2DM is insulin resistance. 
Endogenously, insulin acts to dispose of glucose within the skeletal 
muscle as well as to suppress hepatic glucose production. A patient is 
considered to have insulin resistance when these endogenous effects 
of insulin are decreased. The early stages of T2DM are often marked 
by hyperinsulinemia accompanied by accelerated endogenous glucose 
production. Hepatic insulin resistance is considered the major contributor 
to hyperglycemia in these patients. Cytokines, hormones and non-
esterified fatty acids (NEFA} all moderate insulin action and arise in the 
adipocytes. A rise in triglyceride stores increases adipocyte size and 
alters the ability of insulin to suppress lipolysis. This leads to high circu-
lating levels of NEFA and glycerol, which cause insulin resistance in the 
liver and skeletal muscle. Ectopic fat storage (fat storage in non-adipose 
cells) also may intensify insulin resistance. The American Association of 
Clinical Endocrinologists suggests T2DM diagnosis be based on the pres-
ence of one of three factors:5 Symptoms of diabetes, such as polyuria, 
polydipsia and unexplained weight loss, and the causal plasma glucose 
concentrations> 200 mg/dl, fasting glucose concentration> 126 mg/dl, 
or a two-hour post-challenge glucose concentration ~ 200 mg/dl during a 
75 g oral glucose tolerance test. 
The 201 O American Diabetes Association (ADA) Standards of Care Guide-
lines recommend that a physician-coordinated team, including the phar-
macist, oversee the management of diabetes and provide the patient with 
proper medical nutrition therapy and diabetes self-management education. 6 
For glucose management, the ADA recommends self-monitoring of blood 
glucose (if on insulin), testing HbA 1 c two to four times yearly dependent on 
patient's blood glucose control, and initiating metformin therapy and lifestyle 
changes at the time of diagnosis with medicinal therapy augmentation as 
needed. Furthermore, diabetes leads to accelerated development of micro 
and macrovascular disorders. Cardiovascular disease is the leading cause 
of morbidity and mortality among diabetic patients. The guidelines therefore 
indicate that blood pressure control, lipid management and aspirin therapy as 
needed, in addition to proper screening and treatment for coronary heart dis-
ease, nephropathy, retinopathy and neuropathy, are important components 
of care. Finally, for the first time, the ADA has included bariatric surgery as a 
treatment option for those patients with a BMI > 35 and concurrent T2DM in 
their 201 O guidelines. 
Bariatrlc surgery 
Due to the evident association between obesity and diabetes, many re-
searchers are exploring the option of bariatric surgery for diabetes manage-
ment and possibly disease reversal. Currently, four types of gastric bypass 
are generally performed. The adjustable gastric band (AGB) is a band that 
can be placed around the top of the stomach to form a smal I pouch. 7 Band 
size is controlled by modifying the amount of saline solution in the band in 
order to increase or decrease the size of the band's circular balloon, thereby 
altering stomach outlet size. In Roux-en-Y gastric bypass (RYGB), digestive 
tract size is reduced through bypassing most of the stomach, duodenum 
and upper intestine. This not only limits food intake to that which can fit in a 
small pouch, but also decreases gastrointestinal absorption. Biliopancreatic 
diversion with a duodenal switch (BPD-DS) consists of a reduction in stom-
ach size to reduce food intake, a redirection of food away from the small 
intestine to drastically decrease absorption, and a redirection of bile and 
digestive juices to impair digestion. Typically, BPD-DS results in the most 
weight loss but also has the highest risk of long-term complications because 
of the malabsorption that results. Lastly, vertical sleeve gastrectomy (VSG), 
one of the three components of BPD-DS, drastically reduces stomach 
size as mentioned previously. This size reduction also may decrease the 
amount of ghrelin produced, reducing hunger to a greater extent than the 
lap band operation and aiding in patient success. 
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Gastrolntestlnal 
How it works 
Since the 1980s, research has been conducted to assess the efficacy of 
using gastric bypass surgery for the treatment of T2DM, and, as previ-
ously stated, the ADA has recently included gastric bypass as a thera-
peutic option for T2DM within their guidelines.2•6 Scientists hypothesized 
that the excessive amount of weight loss resulting from the surgery may 
diminish the symptoms of T2DM. It has been verified that surgery is the 
most effective way to produce sustained and substantial weight loss in 
patients.8 The weight reduction strategies that have been used include 
gastric restriction via the reduction of stomach volume and intestinal 
malabsorption due to the shortening of the small intestine and decreas-
ing the surface area available for nutrient absorption.9 
One of the main surgeries currently being investigated that has shown the 
most promising results is RYGB. During this surgery, the stomach is divid-
ed into two sections, where a small stomach pouch (15-30 ml in volume) 
is formed in the upper part of the stomach by using surgical staples or a 
gastric band.2 This small pouch is directly connected to the middle portion 
of the jejunum, thus bypassing the lower part of the stomach, the duode-
num and part of the jejunum. Gastric juices, bile and pancreatic enzymes 
continue to flow from the lower part of the stomach and duodenum through 
the small intestines and meet the other channel at a Y-shaped junction. 
Improvement of T2DM using RYGB is thought to be a result of a 
combination of weight loss, decreased caloric intake, hormonal changes 
and rearrangement of gastrointestinal anatomy. 2 The amount of overall 
weight loss does not prove to be the primary mechanism of treatment 
for diabetes because the resolution of diabetes occurs within days after 
surgery, prior to the majority of the weight loss. Complete eradication 
of the disease, however, is seen more frequently in those patients who 
lose more weight. It has been observed that the decreased caloric intake 
resulting from RYGB may help with short-term glycemic control, but 
overall resolution of T2DM cannot be accounted for due to decrease 
in caloric intake. Hormonal changes are thought to be one of the main 
reasons for this possible success in T2DM. RYGB has shown to result in 
increased levels of GLP, Peptide YY (PYY), adiponectin and decreased 
levels of GIP, acylation-stimulating protein (ASP), leptin, and ghrelin. 
These hormones have a major impact on the function of the GI tract and, 
when altered due to RYGB, may lead to many of the positive effects of 
the surgery (table 1 ). 
Table 1 ·Effect of RYGB on Gastrointestinal Tract (GIT) Hormones2 
Hormone Increase/Decrease in Hormone 
following RVGB 
Benefits 
Diabetes often is a life-altering and life-defining disease that many 
individuals have difficulty managing. Gastric bypass surgery can be 
very beneficial for some patients that have had difficulty in achieving 
adequate diabetes control. Positive outcomes resulting from the surgery 
include decreased mortality rates, normalization of HbA 1 c levels, 
decreased dependence on diabetic medications, and increased insulin 
sensitivity. A study including 608 morbidly obese patients that were 
followed for 14 years post-gastric bypass operation reported an average 
excess weight loss of 49 percent.90f the 608 patients, 330 had either di-
abetes (n= 165) or impaired glucose tolerance (n= 165) at baseline. At the 
end of the study, 82 percent of those with T2DM had normal HbA 1 c lev-
els. Another study including 232 morbidly obese patients, all with T2DM, 
was conducted to assess long-term mortality rates. It was found that the 
mortality rate of the control group was significantly higher (P<0.0003) 
than the surgical group. The number of cardiovascular deaths was the 
major variant between the two groups. By decreasing mortality rates and 
HbA 1 c levels, a diabetic patient may have a prolonged and better quality 
of life. 
Once diagnosed with diabetes, it is rare that there will be a day that a 
patient will go without taking a pill again. Gastric bypass has shown to 
minimize the number of medications needed for a diabetic patient, which 
will help with patient compliance issues and allow for simpler medica-
tion therapy.2 In general, RYGB shows a reduction in the dependence 
on diabetic medication of 80-98 percent of patients for up to 14 years 
of follow-up. Surgery is more effective than medicinal treatment alone 
for improving diabetes for long-term effects. A study comparing 154 
morbidly obese type 2 diabetics that had gastric bypass surgery to 78 
control patients showed that 87 percent of the control group required 
medication intervention after nine years of follow-up. After 6.2 years 
of follow-up, medication intervention required for the surgery group fell 
from 31 percent to 9 percent. Another study, which included 378 type 2 
diabetic patients that underwent weight reduction surgery, 72 of which 
were medicated, showed that there was a significant reduction in blood 
sugar level from 9.1 mmol/L (preoperative) to 6.6 mmol/L (postoperative) 
with a P=0.005.8 Of the 72 patients who were medicated, 36 patients 
had stopped all medication for diabetes, and none had an increase in 
dose post-operation. There was a 75 percent reduction in patients that 
Endogenous Effect 
GLP-1 Increase Acts to suppress glucagon, reduce glucose production by the liver, 
increase insulin production, slow gastric emptying, and enhance satiety 
GIP Decrease Stimulates insulin release and synthesis 
ASP Decrease Increased glucose uptake and fatty acid esterification 
Ghrelin Decrease Appetite-stimulating hormone 
pyy Increase Decreases food intake by inhibiting gut motility 
Adiponectin Increase Stimulates glucose utilization and fatty acid oxidation in skeletal muscle 
lncretin Decrease Secreted after meals to enhance insulin secretion 
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required insulin after the operation. Sixty-nine percent of all patients 
that underwent RYGB surgery as the weight reduction surgery were 
off all medications post-operation (P<0.0001 ). There was no significant 
relationship between the amount of weight loss and change in diabetic 
status. While a complete reversal of diabetes may be life-changing for 
an individual, a reduction in diabetes medication use in those who do not 
achieve complete reversal also can be very beneficial. Currently avail-
able studies have generally shown a decreased need for medications 
following gastric bypass surgery for the diabetic patient. More studies 
need to be performed to further confirm and more accurately assess the 
benefits and mechanisms surrounding this matter. 
One of the most challenging issues for diabetic patients is glucose con-
trol. It is a constant struggle for doctors and pharmacists to counsel pa-
tients on ways to minimize fluctuations in glucose levels. Gastric bypass 
may be a beneficial option for patients who struggle to maintain normal 
glucose levels. After gastric bypass surgery, a normalization of glucose 
metabolism is often seen within weeks of surgery.2 Long-term effects are 
better seen within two to five years post-operation. In a trial investigating 
4,047 subjects treated for obesity, 72 percent of the patients surgically 
treated recovered from T2DM within two years of surgery, compared to 
only 21 percent of the control group. 
Gastric bypass has shown its best effects in its long-term treatment of 
T2DM. A resolution rate of diabetes is between 83-85 percent in the long 
term for gastric bypass surgery. 8 RYGB is more effective for the treat-
ment of T2DM in patients with a milder form and a shorter duration of the 
disease.2 Patients who do not experience significant improvement from 
the surgery tend to be older. Unlike insulin sensitivity, B cell function 
improvement is more closely related to duration of diabetes rather than 
weight loss.9 While gastric bypass surgery has proven to show many 
benefits for the treatment of T2DM, these benefits should be weighed 
against the risks of surgery before using this method in any patient. Also, 
the characteristics of the patient must be considered in determining if 
qualifications for this surgery are met, including obesity and BMI criteria. 
Risks 
Along with any surgery comes risk of treatment, possible complications 
and death, in addition to potential hardships from expenses and medical 
bills. Figures show that there is less than 1 percent risk of mortality for 
patients undergoing RYGB, and a risk of complications range from less 
than 1 o to 20 percent. 8 Medical bills for RYGB, including hospital stays, 
anesthesia, lab costs and surgeon fees, costs approximately $26,000 
without health insurance. 10 Insurance coverage varies from plan to plan, 
but bariatric surgery is frequently not covered in full, if at all. 
Complications of these operations include bleeding, infection and blood 
clots that can move to the heart or lungs.7 Later problems, such as 
malnutrition, strictures and hernias, also may occur. Studies suggest that 
up to 1 O percent of patients receiving bariatric surgery may experience 
inadequate weight loss or may regain much of the weight that is initially 
lost. Experts recommend that these procedures be performed only on 
adolescents that are extremely obese (typically with BMI greater than 
40), have reached their adult height (usually 13 or older for girls and 15 or 
older for boys), and have serious weight-related health problems, such as 
T2DM, sleep apnea, heart disease, or significant functional or psychoso-
cial impairment. Surgery should only be considered after candidates have 
attempted weight reduction for at least six months and have failed. 
Following RYGB, the risk of developing vitamin and mineral deficiency 
is significantly increased. RYGB can lead to decreased levels of vitamin 
812, fol ate, iron and calcium either through malabsorption or insufficient 
intake.11 Supplementation of these specific vitamins is vital following 
RYGB surgery. 
Cost Analysis 
As previously mentioned, comprehensive medical costs for RYGB 
without insurance are an estimated $26,000.10 Insurance coverage varies, 
and, if coverage is provided, it normally does not cover the entire cost 
of surgery. Comparatively, a 201 O study employed a Cost of Diabetes 
Model to estimate the U.S. economic burden related to diabetes.12 The 
study analyzed information from peer-reviewed literature, government 
statistics and national survey, and medical claim databases. The average 
annual cost per patient standardized to 2007 dollar amounts was $2,864 
for undiagnosed diabetes and $9,677 for diagnosed T2DM. As a refer-
ence, the median age of diagnoses for T2DM was 57 with annual costs 
increasing with age. Depending on quality of insurance coverage, length 
of life, age of diagnosis and success of surgery in treatment of symptoms, 
gastric bypass offers potentially great long-term cost savings, although the 
actual magnitude of these savings is still to be determined. More cost-
effectiveness studies need to be completed to fully and more adequately 
compare the costs of bariatric surgery as treatment for T2DM versus the 
current standard of care. 
Effect on Drug Absorption 
Data examining the effect of bariatric surgery on drug absorption is lack-
ing. A recent review of the literature suggests that, although there is little 
known, the effect of bariatric surgery on drug absorption appears to be 
drug-specific.13 In some cases, substantial reductions in drug absorption 
may occur, which may be temporally associated with the need for dosage 
adjustment. Overall, evidence for decreased drug absorption was found 
in 15 of 22 studies involving jejunoileal bypass, one of three studies of 
gastric bypass/gastroplasty, and none in the one study examining bil-
iopancreatic diversion. Specifically, multiple reports described decreased 
absorption for anti-rejection drugs (cyclosporine and tacrolimus}, thyrox-
ine, phenytoin and rifampin. Single instances of diminished absorption 
of ethosuximide, amoxicillin, macrodantin, tacrolimus, sulfisoxazole and 
hydrochlorothiazide were reported. Conflicting evidence was present for 
ethambutol, digoxin and oral contraceptives. Further study is needed 
to assess the degree of malabsorption specific to each medication and 
whether there are major differences among procedure types that exist.13 
Conclusion 
Gastric bypass, specifically RYGB, appears to be a promising treatment 
for T2DM. RYGB not only slows progression of the disease, but also offers 
potential disease resolution. The average long-term diabetes resolution 
rate for those who undergo surgery is an impressive 83-85 percent, which 
considerably improves quality and duration of life, achieved through a 
significant reduction in diabetes-associated complications. Also, it is 
suspected that a cost savings will be incurred through medication reduc-
tion or cessation. Although RYGB has shown great success, studies have 
revealed better outcomes in younger individuals newer to diagnosis with a 
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milder form of the disease. RYGB as a treatment for T2DM should be re-
stricted to patients with a BMI > 35 with concurrent diabetes, due to po-
tential complications of surgery and limited research support beyond use 
in other populations. Patients should be able and willing to exhibit high 
levels of compliance to current medication therapy, as physician visits 
and daily vitamin supplementation will be required following surgery. It 
is vltal that patients comply with continual follow-up visits to promote 
optimal results. Much focus should be placed on these parameters when 
electing candidates for surgery. This strategy has grabbed the atten-
tion of many health care professionals, and with 30 years of supporting 
research, gastric bypass now has been included in clinical guidelines as 
an appropriate treatment option for some T2DM patients. 
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